|
Beijing Strong Biotechnologies, Inc. (300406.SZ) DCF Valuation
CN | Healthcare | Medical - Diagnostics & Research | SHZ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Beijing Strong Biotechnologies, Inc. (300406.SZ) Bundle
Gain insight into your Beijing Strong Biotechnologies, Inc. (300406SZ) valuation analysis using our sophisticated DCF Calculator! Preloaded with authentic (300406SZ) data, this Excel template enables you to adjust forecasts and assumptions to accurately calculate the intrinsic value of Beijing Strong Biotechnologies, Inc. (300406SZ).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 840.9 | 848.1 | 1,599.4 | 1,510.9 | 1,741.6 | 2,173.5 | 2,712.4 | 3,384.9 | 4,224.3 | 5,271.7 |
| Revenue Growth, % | 0 | 0.86302 | 88.58 | -5.53 | 15.27 | 24.8 | 24.8 | 24.8 | 24.8 | 24.8 |
| EBITDA | 405.2 | 178.3 | 604.6 | 556.8 | 698.0 | 799.6 | 997.8 | 1,245.2 | 1,554.0 | 1,939.3 |
| EBITDA, % | 48.18 | 21.02 | 37.8 | 36.85 | 40.08 | 36.79 | 36.79 | 36.79 | 36.79 | 36.79 |
| Depreciation | 21.9 | 31.7 | 45.5 | 55.7 | 57.2 | 70.2 | 87.6 | 109.4 | 136.5 | 170.3 |
| Depreciation, % | 2.6 | 3.74 | 2.84 | 3.69 | 3.28 | 3.23 | 3.23 | 3.23 | 3.23 | 3.23 |
| EBIT | 383.3 | 146.6 | 559.1 | 501.1 | 640.8 | 729.3 | 910.2 | 1,135.9 | 1,417.5 | 1,769.0 |
| EBIT, % | 45.58 | 17.28 | 34.96 | 33.17 | 36.79 | 33.56 | 33.56 | 33.56 | 33.56 | 33.56 |
| Total Cash | 225.7 | 582.3 | 382.5 | 340.7 | 724.0 | 797.8 | 995.7 | 1,242.5 | 1,550.6 | 1,935.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 575.7 | 770.3 | 949.0 | 1,039.0 | 1,144.6 | 1,535.0 | 1,915.6 | 2,390.6 | 2,983.3 | 3,723.1 |
| Account Receivables, % | 68.47 | 90.82 | 59.33 | 68.77 | 65.72 | 70.62 | 70.62 | 70.62 | 70.62 | 70.62 |
| Inventories | 149.5 | 247.4 | 252.0 | 219.7 | 229.7 | 393.2 | 490.6 | 612.3 | 764.1 | 953.6 |
| Inventories, % | 17.78 | 29.18 | 15.76 | 14.54 | 13.19 | 18.09 | 18.09 | 18.09 | 18.09 | 18.09 |
| Accounts Payable | 24.0 | 42.3 | 47.1 | 37.7 | 81.7 | 78.1 | 97.5 | 121.6 | 151.8 | 189.4 |
| Accounts Payable, % | 2.85 | 4.99 | 2.95 | 2.49 | 4.69 | 3.59 | 3.59 | 3.59 | 3.59 | 3.59 |
| Capital Expenditure | -61.4 | -17.2 | -65.2 | -96.5 | -148.0 | -123.0 | -153.5 | -191.6 | -239.1 | -298.4 |
| Capital Expenditure, % | -7.3 | -2.03 | -4.08 | -6.39 | -8.5 | -5.66 | -5.66 | -5.66 | -5.66 | -5.66 |
| Tax Rate, % | 11.76 | 11.76 | 11.76 | 11.76 | 11.76 | 11.76 | 11.76 | 11.76 | 11.76 | 11.76 |
| EBITAT | 332.8 | 120.2 | 422.3 | 433.9 | 565.5 | 611.5 | 763.1 | 952.3 | 1,188.5 | 1,483.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -408.0 | -139.5 | 224.2 | 326.0 | 402.9 | 1.3 | 238.5 | 297.6 | 371.4 | 463.5 |
| WACC, % | 5.93 | 5.91 | 5.88 | 5.93 | 5.94 | 5.92 | 5.92 | 5.92 | 5.92 | 5.92 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,107.3 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 480 | |||||||||
| Terminal Value | 19,857 | |||||||||
| Present Terminal Value | 14,897 | |||||||||
| Enterprise Value | 16,004 | |||||||||
| Net Debt | 408 | |||||||||
| Equity Value | 15,597 | |||||||||
| Diluted Shares Outstanding, MM | 595 | |||||||||
| Equity Value Per Share | 26.21 |
Benefits You Will Receive
- Pre-Loaded Financial Model: The actual data from Beijing Strong Biotechnologies (300406SZ) provides an accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential parameters to suit your analysis.
- Real-Time Calculations: Automatic updates allow you to view outcomes instantly as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for serious investment valuation.
- Flexible and Reusable: Designed for adaptability, enabling repeated applications for in-depth forecasting.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Beijing Strong Biotechnologies, Inc. (300406SZ).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with customizable parameters.
- Adjustable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Beijing Strong Biotechnologies, Inc. (300406SZ).
- Dynamic Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Functions
- Step 1: Download the Excel spreadsheet.
- Step 2: Examine the pre-populated data for Beijing Strong Biotechnologies, Inc. (300406SZ).
- Step 3: Modify the key assumptions (highlighted in yellow) based on your analysis.
- Step 4: Observe the automatic updates reflecting the intrinsic value of Beijing Strong Biotechnologies, Inc. (300406SZ).
- Step 5: Leverage the results for investment analysis or reporting purposes.
Why Opt for This Calculator?
- Time-Saving: Eliminate the hassle of building a DCF model from scratch – it’s ready for immediate use.
- Enhanced Accuracy: Dependable financial data and formulas minimize valuation errors.
- Completely Customizable: Adapt the model to align with your assumptions and forecasts.
- User-Friendly: Intuitive charts and outputs facilitate easy interpretation of results.
- Endorsed by Professionals: Crafted for experts who prioritize precision and usability.
Who Can Benefit from This Product?
- Individual Investors: Gain insights to make informed decisions regarding investments in Beijing Strong Biotechnologies, Inc. (300406SZ).
- Financial Analysts: Enhance your valuation processes with comprehensive financial models tailored for the biotech sector.
- Consultants: Provide your clients with expert valuation analysis for rapid and precise insights.
- Business Owners: Learn how major biotech firms like Beijing Strong Biotechnologies, Inc. (300406SZ) are valued to inform your own business strategy.
- Finance Students: Study valuation methodologies using real-life data and case studies from the biotechnology industry.
Contents of the Template
- Historical Data: Contains Beijing Strong Biotechnologies Inc.'s past financial performance and baseline projections.
- DCF and Levered DCF Models: Comprehensive templates for calculating the intrinsic value of Beijing Strong Biotechnologies Inc. (300406SZ).
- WACC Sheet: Pre-configured calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Customize essential metrics such as growth rates, EBITDA percentages, and CAPEX assumptions.
- Quarterly and Annual Statements: Detailed breakdown of the financial statements of Beijing Strong Biotechnologies Inc. (300406SZ).
- Interactive Dashboard: Dynamic visualization of valuation outcomes and future projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.